Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent ...

Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin ... the cost of insulin products in the US marketplace – agreed ...

It also needs to make a success of inhaled insulin Afrezza ... unit – emerging markets – bundles Sanofi's generic medicines and older products still in patent with the company's consumer ...

Insulin pump therapy ... to consider the interactions of users with the technical features of their products is limited. The clinical studies required by regulators prior to marketing are small ...

“Supply chain issues and the dominance of a few pharmaceutical companies keep prices of some products high and ... the ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs).

Today, Sanofi and Breakthrough T1D UK announce a special collaboration with Beano, to mark World Diabetes Day, 14th November ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...